{"url_path":"/sec/tpst/8-k/2026-07-22/cover-page","section_key":"cover-page","section_title":"Cover Page","topic":"sec","document":{"doc_type":"8-K","doc_date":"2026-07-22","source_url":"https://www.sec.gov/Archives/edgar/data/1544227/0001193125-26-312391-index.html","accession_number":"0001193125-26-312391","cik":"0001544227","ticker":"TPST","issuer_name":"Tempest Therapeutics, Inc.","edgar_url":"https://www.sec.gov/Archives/edgar/data/1544227/0001193125-26-312391-index.html","primary_entity_key":"0001544227","primary_entity_name":"Tempest Therapeutics, Inc."},"word_count":330,"has_tables":true,"body_markdown":"8-K\n\nfalse 0001544227 0001544227 2026-07-17 2026-07-17 0001544227 us-gaap:CommonStockMember 2026-07-17 2026-07-17 0001544227 us-gaap:SeriesAPreferredStockMember 2026-07-17 2026-07-17\n\n \n\n \n\nUNITED STATES\n\nSECURITIES AND EXCHANGE COMMISSION\n\nWASHINGTON, D.C. 20549\n\n \n\n \n\nFORM 8-K\n\n \n\n \n\nCURRENT REPORT\n\nPursuant to Section 13 or 15(d)\n\nof the Securities Exchange Act of 1934\n\nDate of Report (Date of earliest event reported): July 17, 2026\n\n \n\n \n\nTempest Therapeutics, Inc.\n\n(Exact name of Registrant as Specified in Its Charter)\n\n \n\n \n\n \n\nDelaware\n \n001-35890\n \n45-1472564\n\n(State or Other Jurisdiction\nof Incorporation)\n \n\n(Commission\n\nFile Number)\n\n \n(IRS Employer\nIdentification No.)\n\n \n\n2000 Sierra Point Parkway, Suite 400\n \n\nBrisbane, California\n \n94005\n\n(Address of Principal Executive Offices)\n \n(Zip Code)\n\nRegistrant’s Telephone Number, Including Area Code: (415) 798-8589\n\n(Former Name or Former Address, if Changed Since Last Report)\n\n \n\n \n\nCheck the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:\n\n \n\n☐\n\nWritten communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)\n\n \n\n☐\n\nSoliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)\n\n \n\n☐\n\nPre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))\n\n \n\n☐\n\nPre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))\n\nSecurities registered pursuant to Section 12(b) of the Act:\n\n \n\nTitle of each class\n\n \n\nTrading\nSymbol(s)\n\n \n\nName of each exchange\non which registered\n\nCommon Stock, $0.001 par value\n \nTPST\n \nThe Nasdaq Stock Market LLC\n\nSeries A Junior Participating Preferred Purchase Rights\n \nN/A\n \nThe Nasdaq Stock Market LLC\n\nIndicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).\n\nEmerging growth company ☐\n\nIf an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐"}